Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
Mark W Stolar,1 Michael Grimm,2 Steve Chen2 1Clinical Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Amylin Pharmaceuticals, LLC, San Diego, CA, USA Abstract: Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time p...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f96844b882ed41e1a97c974166290ed4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|